U.S. and European specialists have proposed a joint follow guideline to be used in nuclear medication on diagnostics and remedy (theranostics) of meningiomas, as printed June 20 within the European Journal of Nuclear Medication and Molecular Imaging.
The process requirements focus particularly on the technical points of somatostatin receptor (SSTR) ligands, which can be utilized in each PET imaging and therapy of meningiomas, and are supposed to guarantee efficient use of the strategy, famous lead writer Nathalie Albert, of Ludwig Maximilian College in Munich.
“The medical utilization of SSTR-directed PET/CT imaging and [peptide receptor radionuclide therapy, or PRRT] amongst sufferers with meningioma has proven a constant rise in Europe and the U.S.,” the group wrote.
Theranostics consists of utilizing an imaging tracer for in-vivo visualization of a tumor-specific goal, which is then addressed by the identical or analogous molecule labeled with a therapeutic radionuclide as a substitute of the diagnostic radionuclide.
Specialists within the subject have described the idea with the expression, “See what you deal with and deal with what you see.”
The strategy is already efficiently utilized in neuroendocrine tumor sufferers and preliminary PRRT research present encouraging outcomes with favorable outcomes in sufferers with treatment-refractory meningioma, the group famous. But randomized medical trials on the efficacy of PRRT in meningiomas are lacking and PRRT isn’t but permitted for meningioma sufferers by U.S. or European medical companies, they added.
Thus, the authors developed this follow guideline with the next targets:
- To help healthcare professionals, notably nuclear medication practitioners, in recommending, deciphering, and reporting the outcomes of mind SSTR-PET imaging in meningiomas.
- To outline process requirements for the applying of SSTR PET imaging in meningiomas and SSTR-targeted PRRTs in medical follow and medical trials to be able to facilitate harmonization of information acquisition and therapy protocols throughout facilities.
The rule of thumb covers indications and contraindications, {qualifications} and obligations of personnel — together with physicists and technologists — procedures and specs, documentation and reporting, gear specs, and high quality management enchancment.
“With a view to carry SSTR-directed PET/CT imaging in addition to SSTR-directed radionuclide remedy of meningiomas into day by day medical follow and to extend the proof stage of this extremely promising theranostic strategy, adequately designed and managed potential multicenter trials are strongly inspired,” the group wrote.
The authors symbolize the European Affiliation of Nuclear Medication (EANM), the Society of Nuclear Medication and Molecular Imaging (SNMMI), the European Affiliation of Neurooncology (EAN), and the PET job drive of the Response Evaluation in Neurooncology Working Group (RANO).
The complete article is on the market right here.
